Wait, didn't Alcon just try to buy them? If you’ve been watching the STAAR Surgical stock price lately, you know it's basically been a roller coaster with no seatbelts. One minute there's a $30.75 per share buyout offer on the table, and the next, the deal is falling through or getting delayed so many times it feels like a bad Netflix sequel.
Honestly, it’s a mess. But for an investor, this kind of mess is exactly where the money is usually made—or lost.
💡 You might also like: General Mills Stock Price: What Most People Get Wrong About the Cereal Giant
The Current Reality of STAA
As of mid-January 2026, we’re looking at a price hovering around $20.97. It’s a far cry from that $162 peak we saw back in 2021. If you bought then, I’m sorry. Truly. But the "right now" is what matters. The stock just took a nearly 4% hit in a single day, and the market cap is sitting right at $1.04 billion.
Why the drama? Well, the Alcon merger was supposed to be the "get out of jail free" card for shareholders. Alcon offered $30.75. Then they postponed the vote. Then they did it again. Now, with the deal essentially in limbo and leadership changing hands—CEO Stephen Farrell is stepping down at the end of January—the market is spooked.
The China Problem (And Why It’s Still a Problem)
You can't talk about the STAAR Surgical stock price without talking about China. For years, China was the golden goose. Myopia (nearsightedness) is an epidemic there, and STAAR’s EVO ICL lenses were the "luxury" alternative to LASIK.
But then the macro-environment hit a wall.
In 2025, the numbers were brutal. In the first half of the year, sales in China plummeted because distributors were sitting on way too much inventory. They weren't buying new lenses because they couldn't move the old ones. We saw revenue drops of 45% to 55% in the early quarters of 2025.
- Inventory Bloat: Distributors had to burn through $80 million to $85 million of stock before ordering more.
- The "December Shipment" Miracle: In Q3 2025, STAAR reported $94.7 million in sales. Sounds great, right? Except $25.9 million of that was just a late payment from a shipment made all the way back in December 2024.
- Consumer Confidence: Young people in China aren't spending like they used to. A $3,000 eye surgery is a hard sell when you're worried about the housing market.
Is the EVO ICL Still a "Killer App"?
Despite the stock price carnage, the tech is actually solid. I've talked to surgeons who swear by the Collamer lens. Unlike LASIK, which shaves off your cornea, the ICL is like a permanent contact lens inside your eye. If you don't like it, a doctor can literally just take it out. That "reversibility" is a massive selling point.
Outside of China, things aren't actually that bad. Sales in the rest of the world grew about 7.7% in late 2025. Japan and South Korea remain strong. Even the U.S. is picking up. But when China is 50%+ of your business, "not that bad" everywhere else doesn't stop the bleeding.
💡 You might also like: Reserve Bank of India Rate Cut: Why the Long Wait is Finally Ending
What the Analysts Are Saying (It’s Not Pretty)
If you look at the big banks, the vibe is... cautious. Morgan Stanley recently doubled down on an "Underweight" rating with a price target of $13.00. That’s a terrifying number if you're holding at $21. They’re basically saying the company is worth way less than the current market price because the growth just isn't there anymore.
On the flip side, some analysts still have targets up near $26 or $30, holding out hope that once the inventory issues in China clear up, the "true" growth will return.
- The Bull Case: The Alcon deal eventually goes through at a premium, or the company returns to double-digit growth in 2026 as its Switzerland manufacturing plant lowers costs.
- The Bear Case: The Alcon deal dies for good, China’s economy stays in the basement, and STAAR continues to lose money (the EPS is currently a painful -$1.96).
The Leadership Shakeup
Stephen Farrell is out. That's a big deal. When a CEO leaves during a period of extreme volatility, it usually means the Board wants a different direction—or the person in charge is tired of fighting the uphill battle. New board members from Broadwood Partners and Yunqi Capital are moving in. These are "activist" style moves. They want to squeeze value out of the company, which usually means cutting costs or forcing a sale.
How to Play the STAAR Surgical Stock Price Right Now
If you're looking at STAA, you're not buying a steady utility stock. You're betting on a turnaround or a buyout.
Don't ignore the technicals. The stock is trading below its 50-day moving average ($25.24). In "trader speak," that means the momentum is downward. Catching a falling knife is a great way to get cut.
Watch the Alcon headlines. If a definitive "no" comes out regarding the merger, expect a sharp drop. If the deal gets re-upped or confirmed, you’ll see a gap up toward that $30 mark.
Look at the earnings, not the "preliminary" results. STAAR has a habit of using accounting "timing" (like that China shipment) to make quarters look better than they are. Look at the net income. They lost $54 million in Q1 2025. That’s a lot of cash burning.
Actionable Insights for Investors
If you’re thinking about jumping in, here’s the move:
🔗 Read more: Why What's the Price of an Ounce of Gold Today Still Matters for Your Portfolio
Wait for the Q4 2025 and Full Year 2025 final audited results (usually out in February). You need to see if the "organic" growth—meaning sales not tied to old 2024 shipments—is actually recovering. If China sales are still stagnant without the accounting tricks, the STAAR Surgical stock price has more room to fall.
Keep an eye on the $17.20 level. That’s the average price the company itself was paying to buy back its own shares in 2025. If the company thinks $17 is a deal, that might be your "floor." But in this market? Floors can turn into trap doors pretty fast.
Position sizing is everything here. This isn't a "bet the farm" stock. It's a "speculative 2% of my portfolio" stock. The technology is world-class, but the business side is currently in the ICU.
Check the SEC filings for Form 4s. If the new board members start buying shares with their own money, that’s your strongest signal. Until then, it's a waiting game.